Observational studyEuropean heart journal2024
Oral anticoagulation after atrial fibrillation catheter ablation: benefits and risks.
Observational study in European heart journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Clinical outcomes of continuing vs. discontinuing oral anticoagulation after atrial fibrillation ablation: an updated systematic review and meta-analysis of observational studies and randomized controlled trials.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026Pooled it
- Trial
- Echocardiography-based multimodal models for thromboembolic risk prediction in atrial fibrillation: a narrative review.Journal of thoracic disease · 2026Review
- Residual thromboembolic risk and outcomes of oral anticoagulation discontinuation after atrial fibrillation ablation: a target trial emulation.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026Article
- One Versus Two Months Anticoagulation After Catheter Ablation for Atrial Fibrillation in Patients Who Were Not Indicated for Long-Term OAC: A Pilot Randomized Controlled Trial (The REDUCIBLE Trial).Korean circulation journal · 2026Article
- Reassessing the need for long-term oral anticoagulation following successful atrial fibrillation ablation: a systematic review and meta-analysis.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2026Review
- Compliance to direct oral anticoagulation therapy and clinical outcomes after catheter ablation for atrial fibrillation: a nationwide cohort study.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026Article
- Same Score, Different Risk: Toward Individualized Anticoagulation After Successful AF Ablation: A Narrative Review for the Post-Ablation Antithrombotic Decision in Atrial Fibrillation.Reviews in cardiovascular medicine · 2026Review
- Discontinuation of Oral Anticoagulation After Successful Atrial Fibrillation Ablation - Are We Ready to Change Clinical Practice in 2026?Medical science monitor : international medical journal of experimental and clinical research · 2026Review
- Oral anticoagulation discontinuation after atrial fibrillation ablation: a systematic review and meta-analysis of randomized trials.European heart journal open · 2026Article
- Discontinuation of anticoagulation therapy after atrial fibrillation ablation: the ALONE-AF and OCEAN studies.European heart journal supplements : journal of the European Society of Cardiology · 2026Article
- Erythrocytosis after SGLT2 inhibitor initiation and anticoagulated outcomes in atrial fibrillation: a real-world analysis with counterfactual modeling.Cardiovascular diabetology · 2026Article
- Intelligent mobile health management for the risk of gastrointestinal bleeding in anticoagulated patients with cardiovascular disease.Revista da Escola de Enfermagem da U S P · 2026Observational
- Characterisation and Enhanced Residual Risk Stratification of Long-Term Post-Discharge Ischaemic Events After Atrial Fibrillation Catheter Ablation.TH open : companion journal to thrombosis and haemostasis · 2026Article
- The prevalence and burden of chronic kidney disease, patterns of anticoagulation prescribing, and major bleeding risk in older adults with atrial fibrillation.BMC geriatrics · 2025Article
- The Efficacy of 2-Week Holter Monitoring for Detecting Atrial Tachyarrhythmia Recurrence After Initial Ablation in Patients With Atrial Fibrillation.Journal of arrhythmia · 2025Article
- Stroke prevention in nonvalvular atrial fibrillation: Thoracoscopic left atrial appendage closure with or without surgical ablation.JTCVS techniques · 2025Article
- Current Practice of Guideline-Directed Medical Therapy After Acute Heart Failure Hospitalization: A Nationwide Observational Study.JACC. Asia · 2025Article
- Concise Guidelines of the European Cardiac Arrhythmias Society (ECAS) on "Catheter Ablation of Atrial Fibrillation".Journal of cardiovascular electrophysiology · 2025Article
- Assessment of Long-Term Use Versus Discontinuation of Direct Oral Anticoagulant After Catheter Ablation for Atrial Fibrillation-RYOUMA Registry Subanalysis.Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
Abstract
BACKGROUND AND
aimsFew recent large-scale studies have evaluated the risks and benefits of continuing oral anticoagulant (OAC) therapy after catheter ablation (CA) for atrial fibrillation (AF). This study evaluated the status of continuation of OAC therapy and the association between continuation of OAC therapy and thromboembolic and bleeding events according to the CHADS2 score.
methodsThis retrospective study included data from the Japanese nationwide administrative claims database of patients who underwent CA for AF between April 2014 and March 2021. Patients without AF recurrence assessed by administrative data of the treatment modalities were divided into two groups according to continuation of OAC therapy 6 months after the index CA. The primary outcomes were thromboembolism and major bleeding after a landmark period of 6 months. After inverse probability of treatment weighting analysis, the association between OAC continuation and outcomes was determined according to the CHADS2 score.
resultsAmong 231 374 patients included, 69.7%, 21.6%, and 8.7% had CHADS2 scores of ≤1, 2, and ≥3, respectively. Of these, 71% continued OAC therapy at 6 months. The OAC continuation rate was higher in the high CHADS2 score group than that in the low CHADS2 score group. Among all patients, 2451 patients (0.55 per 100 person-years) had thromboembolism and 2367 (0.53 per 100 person-years) had major bleeding. In the CHADS2 score ≤1 group, the hazard ratio of the continued OAC group was 0.86 [95% confidence interval (CI): 0.74-1.01, P = .06] for thromboembolism and was 1.51 (95% CI: 1.27-1.80, P < .001) for major bleeding. In the CHADS2 score ≥3 group, the hazard ratio of the continued OAC group was 0.61 (95% CI: 0.46-0.82, P = .001) for thromboembolism and was 1.05 (95% CI: 0.71-1.56, P = 0.81) for major bleeding.
conclusionsThis observational study suggests that the benefits and risks of continuing OAC therapy after CA for AF differ based on the patient's CHADS2 score. The risk of major bleeding due to OAC continuation seems to outweigh the risk reduction of thromboembolism in patients with lower thromboembolic risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.